인간 마이크로바이옴 시장 : 예측(2025-2030년)

The human microbiome market will grow at a CAGR of 20.42% to reach US$2,383.317 million in 2030 from US$941.215 million in 2025.

Major factors driving the global human microbiome market growth are increasing instances of lifestyle diseases, diarrheal infections, predominant changes in the lifestyle of the global population, and an increase in the aged population and its applications in healthcare. Moreover, technological enhancements in biomedical sciences and growing research investment in technology and product sectors is also positively impacting the market growth positively. However, lack of awareness about the use and advantages of prebiotics and probiotics and government restrictions on their usage are major challenges for the market players.

Market Trends:

• In-depth analysis of the human microbiome market: The global human microbiome market report delivers a comprehensive examination of the industry landscape, providing strategic and executive-level insights backed by data-driven forecasts and detailed analysis. This report serves as a critical resource for understanding the market's current state and future trajectory, helping stakeholders make informed decisions.
• Actionable insights for decision-makers: Regularly updated, the report equips decision-makers with actionable intelligence on prevailing market trends, emerging opportunities, and competitive dynamics. It offers a deep dive into consumer demand across various regions and product categories, including therapeutics, diagnostics, and probiotics. The report also analyzes purchasing behaviors and identifies key customer segments, such as healthcare providers, pharmaceutical companies, and individual consumers, enabling businesses to tailor their strategies effectively.
• Exploration of technological and regulatory developments: The report further investigates the latest technological advancements in the human microbiome field, such as next-generation sequencing, microbiome-based drug development, and AI-driven diagnostic tools. It also examines the impact of key government policies, regulations, and funding initiatives, such as those related to personalized medicine, clinical trials, and microbiome research. These insights help stakeholders navigate the evolving regulatory landscape and capitalize on growth opportunities in this rapidly advancing market.

Some of the major players covered in this report include Seres Therapeutics, Microbiome Therapeutics Innovation Group, Vedanta Biosciences Inc., Metabiomics, Ferring Pharmaceuticals, Finch Therapeutics, BiomeBank, Biohm Technologies, Resbiotic, Immuron Limited, Maat Pharma among others.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Global Human Microbiome Market Segmentations:

Global Human Microbiome Market Segmentation by product:

• The market analyzed by product into the following:
• Probiotic
• Prebiotics
• Supplements
• Others

Global Human Microbiome Market Segmentation by disease:

• The market analyzed by disease into the following:
• Diabetes
• Autoimmune Disorder
• Cancer
• Obesity
• Others

Global Human Microbiome Market Segmentation by application:

• The market analyzed by application into the following:
• Diagnostics
• Therapeutics

Global Human Microbiome Market Segmentation by regions:

The study also analysed the global human microbiome market into the following regions, with country level forecasts and analysis as below:

• North America (US, Canada and Mexico)
• South America (Brazil, Argentina, and Others)
• Europe (Germany, France, United Kingdom, Spain, Italy and Others
• Middle East and Africa (Saudi Arabia, UAE and Others)
• Asia Pacific (China, India, Japan, South Korea, Thailand and Others)

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL HUMAN MICROBIOME MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Probiotics
• 5.3. Prebiotics
• 5.4. Supplements
• 5.5. Others

6. GLOBAL HUMAN MICROBIOME MARKET BY DISEASE

• 6.1. Introduction
• 6.2. Diabetes
• 6.3. Autoimmune Disorder
• 6.4. Cancer
• 6.5. Obesity
• 6.6. Others

7. GLOBAL HUMAN MICROBIOME MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Diagnostics
• 7.3. Therapeutics

8. GLOBAL HUMAN MICROBIOME MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Italy
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Thailand
  • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Seres Therapeutics
• 10.2. Microbiome Therapeutics Innovation Group
• 10.3. Vedanta Biosciences Inc.
• 10.4. Metabiomics
• 10.5. Ferring Pharmaceuticals
• 10.6. Finch Therapeutics
• 10.7. BiomeBank
• 10.8. Biohm Technologies
• 10.9. Resbiotic
• 10.10. Immuron Limited
• 10.11. Maat Pharma

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations